US pharmaceutical company Azurity Pharmaceuticals announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its Nymalize (nimodipine) oral solution in a 30 mg/5 mL prefilled ENFit syringe.

Delivering Nymalize with ENFit syringes may provide an additional layer of security for patients and healthcare professionals administering medication. ENFit connectors are recommended by the FDA and widespread adoption of ENFit has begun to replace traditional nasogastric tubing. Approximately 60% of all acute care facilities in the USA have adopted ENFit.

According to Azurity, Nymalize offers an effective alternative to capsule extraction for adult subarachnoid haemorrhage patients who cannot swallow capsules. Nymalize is available in ready-to-use prefilled ENFit syringes (30 mg/5 mL), prefilled oral syringes (30 mg/5 mL and 60 mg/10 mL) and in 8 oz (237 mL) bottles. Nymalize may help reduce the risk of fatal medication errors associated with nimodipine capsule extraction.

The Nymalize prefilled ENFit syringe will be available to order through a pharmaceutical wholesaler in the coming weeks.